GlassScriptPhysician profile
Shalini Vijaykumar
NPI 1881827053
$2,567.66
in general payments reported to CMS, 2019-2025
25 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $53.85 · 2021: $197 · 2022: $409 · 2023: $463 · 2024: $589 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.76 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $726.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $490.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $342.96 | 2019-2022 | |
| Abbott Laboratories | $138.14 | 2022-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $98.59 | 2022-2025 | Minimed 780g |
| Mannkind Corporation | $82.16 | 2023 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $69.15 | 2019-2021 | |
| Ibsa Pharma INC. | $67.08 | 2019-2023 | Tirosint, Licart |
| Amgen INC. | $60.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.60 | 2022-2025 | |
| Insulet Corporation | $50.95 | 2024-2025 | Omnipod |
| Beta Bionics, INC. | $45.93 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $40.73 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $40.39 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $34.92 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.81 | 2024 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $24.54 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Becton, Dickinson and Company | $24.43 | 2022 | |
| Bigfoot Biomedical INC | $23.36 | 2022 | |
| Ascendis Pharma Endocrinology INC | $22.65 | 2025 | Yorvipath |
| Glaxosmithkline, LLC. | $21.74 | 2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.65 | 2024 | Jardiance |
| Intuity Medical INC | $17.64 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Antares Pharma, INC. | $17.36 | 2024 | Xyosted |
| Ucb, INC. | $15.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shalini Vijaykumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.